Hybryte(tm): addressing an unmet need for rare lymphoma

Soligenix demonstrates clinical success in first-in-class treatment for cutaneous t-cell lymphomanew york, new york--(newsfile corp. - july 22, 2021) - pcg digital -- cutaneous t-cell lymphoma (ctcl) is a rare form of non-hodgkin's lymphoma that currently affects between 16,000 - 20,000 americans, with approximately 1,000 new diagnoses each year. there is currently no fda-approved first line treatment for ctcl, leaving clinicians and patients reliant on traditional phototherapy treatments. soligenix (nasdaq: sngx), a biopharmaceutical company specializing in treatments for rare diseases, is addressing this unmet need...
SNGX Ratings Summary
SNGX Quant Ranking